Ribavirin-Induced Anemia in Hepatitis C Virus Patients Undergoing Combination Therapy
2011

Modeling Ribavirin-Induced Anemia in Hepatitis C Patients

Sample size: 19 publication 10 minutes Evidence: high

Author Information

Author(s): Krishnan Sheeja M., Dixit Narendra M.

Primary Institution: Indian Institute of Science, Bangalore, India

Hypothesis

Can a mathematical model quantitatively describe ribavirin-induced anemia in hepatitis C patients undergoing combination therapy?

Conclusion

The developed model accurately predicts the dynamics of ribavirin-induced anemia and suggests guidelines for optimizing treatment protocols.

Supporting Evidence

  • Ribavirin improves treatment response but causes hemolytic anemia.
  • The model predicts the threshold ribavirin exposure beyond which anemia becomes intolerable.
  • Inter-patient variability in anemia severity is influenced by ribavirin metabolism.
  • Model predictions align with experimental data from HCV patients.
  • Guidelines for using growth hormones to mitigate anemia are suggested.

Takeaway

This study created a math model to understand how a medicine called ribavirin can cause anemia in patients with hepatitis C, helping doctors find better treatment plans.

Methodology

A mathematical model was developed to describe the population dynamics of erythrocytes in HCV patients treated with ribavirin.

Potential Biases

Potential biases in parameter estimation from fitting the model to patient data.

Limitations

The model relies on assumptions about ribavirin metabolism and may not account for all patient variability.

Participant Demographics

19 Japanese patients with chronic hepatitis C undergoing combination therapy.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pcbi.1001072

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication